Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Hexarelin vs IGF-1 LR3
An educational, source-based comparison of Hexarelin and IGF-1 LR3 — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide and potent GHS-R agonist. Stimulates GH release more strongly than GHRP-6 and shows cardioprotective signaling in preclinical ischemia-reperfusion models, partly independent of GH.
- GH release
- Cardiac ischemia-reperfusion (preclinical)
- Left ventricular function in animal models
- • Not FDA-approved.
- • Tachyphylaxis with prolonged use.
- • Prohibited by WADA.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Hexarelin | Hexarelin and the cardiovascular system | Cardiovascular Research | 2006 | Reviewed direct cardioprotective effects of hexarelin in animal models. |
| IGF-1 LR3 | Long-R3-IGF-I pharmacology and IGFBP interactions | Journal of Endocrinology | 2001 | Characterized extended half-life and bioactivity vs native IGF-1. |
Side-effect & safety grid
- Not FDA-approved.
- Tachyphylaxis with prolonged use.
- Prohibited by WADA.
- Hypoglycemia risk via insulin-receptor cross-activity.
- Not FDA-approved for human therapeutic use; banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Hexarelin vs IGF-1 LR3 — Key differences
- Class: Hexarelin is classified as Growth Hormone Axis · Cardiac, while IGF-1 LR3 is Growth Factor.
- Primary research focus: Hexarelin — gh release; IGF-1 LR3 — muscle protein synthesis (preclinical).
- Tag: Growth hormone vs Growth · Recovery.